AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|AAPL330.49+5.53 (+1.70%) ▲|ABBV260.68-1.04 (-0.40%) ▼|ABT108.84-1.63 (-1.48%) ▼|ACN193.90+6.22 (+3.31%) ▲|ADBE286.31+6.52 (+2.33%) ▲|AMAT435.32-3.14 (-0.72%) ▼|AMD455.80-1.26 (-0.28%) ▼|AMGN442.90+0.06 (+0.01%) ▲|AMT177.25+4.33 (+2.50%) ▲|AMZN258.65+3.67 (+1.44%) ▲|AVGO347.54-19.70 (-5.36%) ▼|AXP330.52+0.54 (+0.16%) ▲|BA207.07-1.80 (-0.86%) ▼|BAC63.11+0.51 (+0.81%) ▲|BKNG198.54-1.06 (-0.53%) ▼|BLK1,116.05+8.97 (+0.81%) ▲|BMY67.55-0.12 (-0.17%) ▼|BNY164.22+2.18 (+1.34%) ▲|BRK-B507.61+2.37 (+0.47%) ▲|C137.73+3.39 (+2.52%) ▲|CAT801.00+8.72 (+1.10%) ▲|CL90.27+0.17 (+0.19%) ▲|CMCSA26.59-0.23 (-0.84%) ▼|COF218.97+2.37 (+1.09%) ▲|COP137.07-0.13 (-0.09%) ▼|COST927.05-1.43 (-0.15%) ▼|CRM264.22+7.29 (+2.84%) ▲|CSCO109.37-0.09 (-0.08%) ▼|CVS97.60+0.37 (+0.38%) ▲|CVX213.02+1.24 (+0.59%) ▲|DE692.91-5.46 (-0.78%) ▼|DHR208.92-0.99 (-0.47%) ▼|DIS107.82-0.16 (-0.15%) ▼|DUK121.56+1.00 (+0.83%) ▲|EMR149.58+0.60 (+0.40%) ▲|FDX320.38+3.84 (+1.21%) ▲|GD362.48-1.59 (-0.44%) ▼|GE332.37+2.87 (+0.87%) ▲|GEV945.25+23.31 (+2.53%) ▲|GILD149.98+0.37 (+0.24%) ▲|GM86.26+1.39 (+1.64%) ▲|GOOG339.54+5.76 (+1.73%) ▲|GOOGL343.03+5.91 (+1.75%) ▲|GS1,036.64+32.22 (+3.21%) ▲|HD317.86+1.68 (+0.53%) ▲|HON206.83+0.76 (+0.37%) ▲|IBM235.25+3.55 (+1.53%) ▲|INTC90.14+0.09 (+0.10%) ▲|INTU349.34+6.40 (+1.87%) ▲|ISRG368.79-3.09 (-0.83%) ▼|JNJ278.07+2.86 (+1.04%) ▲|JPM361.62+5.40 (+1.52%) ▲|KO88.92+0.68 (+0.77%) ▲|LIN483.75-2.10 (-0.43%) ▼|LLY1,152.68-7.41 (-0.64%) ▼|LMT530.78-0.77 (-0.14%) ▼|LOW200.94+1.10 (+0.55%) ▲|LRCX286.57-1.75 (-0.61%) ▼|MA587.11-1.04 (-0.18%) ▼|MCD258.47-2.48 (-0.95%) ▼|MDLZ61.29-1.16 (-1.86%) ▼|MDT92.41+0.23 (+0.24%) ▲|META618.98+26.13 (+4.41%) ▲|MMM167.34-1.41 (-0.84%) ▼|MO69.78+0.22 (+0.32%) ▲|MRK150.44-1.20 (-0.79%) ▼|MS216.99+5.17 (+2.44%) ▲|MSFT512.81+15.99 (+3.22%) ▲|MU945.27-10.81 (-1.13%) ▼|NEE84.11+1.01 (+1.21%) ▲|NFLX82.56-0.17 (-0.21%) ▼|NKE38.21-0.03 (-0.07%) ▼|NOW143.79+7.07 (+5.17%) ▲|NVDA226.98+2.57 (+1.14%) ▲|ORCL152.30+6.55 (+4.49%) ▲|PEP139.66-0.87 (-0.62%) ▼|PFE28.73-0.30 (-1.02%) ▼|PG147.15-0.49 (-0.33%) ▼|PLTR183.42+13.96 (+8.24%) ▲|PM188.56+0.62 (+0.33%) ▲|QCOM169.19+0.15 (+0.09%) ▲|RTX201.25+0.47 (+0.23%) ▲|SBUX106.03-0.69 (-0.65%) ▼|SCHW110.10+1.86 (+1.71%) ▲|SO89.07+0.76 (+0.86%) ▲|SPG211.54+1.34 (+0.64%) ▲|T25.89-0.07 (-0.25%) ▼|TMO611.47+2.93 (+0.48%) ▲|TMUS188.01+0.71 (+0.38%) ▲|TSLA380.40+23.39 (+6.55%) ▲|TXN252.48-2.32 (-0.91%) ▼|UBER75.60-0.86 (-1.12%) ▼|UNH404.94+5.28 (+1.32%) ▲|UNP290.56+0.83 (+0.29%) ▲|UPS102.78-0.23 (-0.22%) ▼|USB63.38+0.61 (+0.96%) ▲|V379.41+1.01 (+0.27%) ▲|VZ50.21-0.01 (-0.02%) ▼|WFC89.61+0.34 (+0.38%) ▲|WMT108.98+2.89 (+2.72%) ▲|XOM164.38+0.23 (+0.14%) ▲|
25.1 C
New York
Thursday, September 3, 2026

Tag: drug

newssourceFORcompanyinformationcontent1releasesmarket

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMD

Landmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory Evaluation

FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)

TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief...

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /PRNewswire/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

Laminar Pharma Announces “Last Patient, Last Visit” in LAM561 Phase 2b/3 Trial for Newly Diagnosed Glioblastoma Patients

PALMA DE MALLORCA, Spain, July 23, 2026 /CNW/ -- Laminar Pharma, a leader in the development of innovative therapies based on a novel membrane lipid...

Harbour BioMed Announces Positive Profit Alert for 2026 Interim Results, Marking Seventh Consecutive Profitable Half-Year as Platform-Based Advantages Drive Sustainable Growth

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, July 23, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery...

Core Axis Introduces Science-Driven Supplement Protocol Developed Specifically for Hashimoto’s Thyroiditis

Cheyenne, Wyoming, July 23, 2026 (GLOBE NEWSWIRE) -- Core Axis, a health brand founded by MC Bio-Logic LLC, announces the upcoming launch of its daily supplement protocol developed with Hashimoto's thyroiditis in mind. Hashimoto's thyroiditis is the autoimmune condition that affects an estimated five million Americans and remains the leading cause of hypothyroidism in the United States. Designed using evidence-based ingredient selection and clinically relevant dosages, the new protocol addresses nutritional factors relevant to individuals with autoimmune thyroid conditions rather than providing general thyroid support. The company is now inviting individuals to join its early access waitlist ahead of the official product launch.

World-Premier Cancer Center Sheba Medical Center Selects Entolimod for Clinical Trial, Potentially Expanding Valion Bio into the Multi-Billion-Dollar Neutropenia Market

Sheba Medical Center, which is ranked the #7 hospital in the world,...

Supreme Court of Canada Upholds Prohibition on Medical Treatment Patents 

MONTREAL, July 20, 2026 (GLOBE NEWSWIRE) -- The Supreme Court of Canada released its highly anticipated decision in Pharmascience Inc. v. Janssen Inc., which addresses the validity of Janssen’s patent relating to the medicine paliperidone. 

Cosmos Health Share Buyback Surpasses $1 Million, Reaching 4.84 Million Shares; Continues Open Market Repurchases

Cosmos Health has now repurchased a total of 4,838,000 shares for approximately $1.04 million.

Has Anyone Tried Gundry MD Phyto Collagen Complex? Read Real Reviews, Ingredients, and Benefits

Plant-Based Collagen Support Designed to Help You Feel Stronger, Look Younger, and Move More FreelyLOS ANGELES, July 14, 2026 /PRNewswire/ -- While many collagen powders...

Keller Logistics Group Steps Up in the National Fight Against Fentanyl, Setting a Standard for the Industry

Unveiled today at the company's Defiance, Ohio headquarters, Truck #6 is part of Hope Hits the Highway - the national naloxone-awareness campaign from Facing...

TBoostExperts.com Announces Availability of 2026 Consumer Report on Testosterone Booster Supplements and Men’s Health Supplement Evaluation

New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research. 
New report provides an educational framework for reviewing testosterone booster supplements, ingredient transparency, supplement labels, consumer safety considerations, and responsible product research.

Decoy Therapeutics, Inc. Announces Up to $21 Million Private Placement Financing

HOUSTON, June 26, 2026 /PRNewswire/ -- Decoy Therapeutics, Inc. (NASDAQ: DCOY) (the "Company" or "Decoy"), a biotechnology company pioneering Designable Multi-Antivirals (D-MAVs™), a new...

Appili Therapeutics Reports Fiscal Year 2026 Financial and Operational Results

LIKMEZ® (ATI-1501) commercial momentum building in U.S. market

US$40 million NIAID award supporting VXV-01 advancement through Phase 1

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsDrug

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers